Health Trials

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

ConditionsSalivary Gland CarcinomaPrecision Therapy
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-100
SponsorPeking Union Medical College

About this trial

Patients with salivary gland carcinoma were divided into groups according to HER2, NTRK, AR, TROP-2, etc. Patients in different groups were given precision targeted therapy or chemotherapy to evaluate the efficacy (ORR rate) and safety of precision therapy.

Eligibility criteria

Qualifiers

Patients with histopathologic diagnosis of salivary gland carcinoma

The tumor tissues were subjected to HER2/NTRK/AR/TROP-2 immunohistochemical staining.

ECOG physical status 0 or 1 score in the 3 days before the first medication of the study treatment;

Age 18 or older - no upper limit;

Disqualifiers

Known hypersensitivity or delayed anaphylaxis to any agents in this trial;

Major surgery had been performed within 4 weeks prior to the start of the study and did not fully recover;

Have received a live vaccine within 4 weeks before the start of the study or plan to receive any vaccine during the study period ;

To study the occurrence of arterial/venous thrombosis events within 6 months before medication;

Trial design

Treatments tested in this trial

  • Cohort 1 (HER2-positive, RC48-ADC)
  • Cohort 2 (NTRK-fusion or NTRK-mutant)
  • Cohort 3 (AR-positive, leuprolide + bicalutamide + abiraterone)
  • TROP2 ADC
  • TKI
  • Albumin-paclitaxel + platinum
  • Albumin-paclitaxel + carboplatin + apatinib + camrelizumab
  • albumin-bound paclitaxel+trastuzumab+pyrotinib
  • HER2,trastuzumab deruxtecan± pertuzumab
  • AR,AR antagonist ++ goserelin + pertuzumab + trastuzumab
  • AR,AR antagonist +goserelin +docetaxel
  • ivonescimab + investigator-choice platinum doublet+
  • iparomlimab + tuvonralimab
  • cadonilimab
  • CDK4/6 inhibitor+AI or fulvestrant
  • alpelisib+fulvestrant
  • PARP inhibitor
  • enfortumab vedotin
  • HER2, pyrotinib + pertuzumab/trastuzumab
  • vebecotutamab ±lenvatinib

Treatment groups

39 Participants
are divided into 20 treatment groups

20

Treatment groups

See each treatment group below.

Sponsors and collaborators

Peking Union Medical College

Lead sponsor

Peking University Hospital of Stomatology

Collaborator

Source ClinicalTrials.gov